Case Details
- Citation: [2025] SGHC(I) 22
- Title: Novo Nordisk A/S v KBP Biosciences Pte. Ltd. & Anor
- Court: Singapore International Commercial Court (SICC)
- Originating Application No: Originating Application No 3 of 2025
- Summons No: Summons No 21 of 2025
- Date: 7, 9 and 11 July 2025; Judgment reserved; 12 August 2025
- Judge: Philip Jeyaretnam J
- Plaintiff/Applicant: Novo Nordisk A/S
- Defendants/Respondents: KBP Biosciences Pte. Ltd. & Huang Zhenhua (Dr Huang)
- Procedural posture: Application to set aside a worldwide freezing order granted ex parte in support of a New York-seated arbitration
- Type of relief sought: Setting aside of a Mareva injunction / worldwide freezing order
- Key statutory provision referenced: Section 12A of the International Arbitration Act 1994 (2020 Rev Ed)
- Statute(s) referenced: International Arbitration Act 1994 (2020 Rev Ed)
- Judgment length: 47 pages; 13,689 words
- Arbitration seat: New York
- Core allegations in arbitration: Fraud relating to KBP’s sale to Novo of a drug developed by KBP (Ocedurenone)
Summary
This decision concerns an application in the Singapore International Commercial Court to set aside a worldwide freezing order (a Mareva injunction) granted ex parte against KBP Biosciences Pte. Ltd. and Dr Huang. The freezing order had been made in aid of a New York-seated arbitration that Novo had commenced (and which alleged fraud in connection with KBP’s sale of the drug Ocedurenone). The defendants challenged the injunction on multiple grounds, including that Novo had no “good arguable case”, that there was no real risk of dissipation, and that Novo had breached the duty of full and frank disclosure. They further argued that the statutory requirements for interim relief under s 12A of the International Arbitration Act 1994 were not satisfied.
After considering the parties’ submissions, Philip Jeyaretnam J dismissed the application and upheld the freezing order. The court accepted that Novo met the threshold for a good arguable case and that the evidence supported a real risk of dissipation. The court also found that the duty of full and frank disclosure had not been breached in a manner warranting discharge. Finally, the court held that its powers under s 12A of the International Arbitration Act 1994 were properly engaged and that it was appropriate for the Singapore court to grant and maintain the interim relief in the circumstances.
What Were the Facts of This Case?
KBP is described as the global headquarters of a biotechnology research and development organisation founded by Dr Huang. Its lead product candidate is a compound known as Ocedurenone, which is said to control blood pressure and provide kidney protection. The development work involved clinical trials conducted in phases, with Phase 2 and Phase 3 being central to the dispute. The judgment emphasises that what Phase 2 truly showed about efficacy—and the consistency of results—was crucial to later decisions and to the commercial value of Ocedurenone.
Phase 2 trials began in April 2018 and were managed by Worldwide Clinical Trials, Inc (“WCT”) as contract research organisation. Phase 2 recruited patients across multiple jurisdictions, including the United States, Chile, Georgia, Bulgaria, Hungary, Israel and Australia. KBP acted as sponsor and appointed Dr George Bakris and Dr Bertram Pitt as lead principal investigators. By 1 June 2020, all patients had been enrolled. In or around January 2020, KBP decided to perform an unplanned administrative interim analysis (“Interim Analysis”) to support manufacturing decisions for Phase 3. A blinding plan was approved and submitted to the US Food and Drug Administration. The Interim Analysis was made available to KBP in June 2020 and was based on data from the first 90 patients to complete week 12 of Phase 2. The Interim Analysis did not show any clear treatment effect of Ocedurenone, and the blinding plan meant that KBP’s clinical team, including the lead PIs, had no knowledge of the Interim Analysis results.
After Phase 2 ended on 5 August 2020, the development and publication record became part of the factual matrix. In January 2021, Dr Bakris, Dr Pitt and others submitted a hypertension-related article (“Hypertension Article”) concluding that Ocedurenone effectively lowers blood pressure; it was accepted and published in July 2021. In June 2021, another article (“EO Article”) was submitted and later published in October 2021, stating that Ocedurenone demonstrated clinical efficacy and safety. A Phase 2 clinical study report (“CSR”) was issued on 6 July 2021 and approved by the lead PIs. KBP’s position was that the Phase 2 CSR demonstrated efficacy not only in Europe but also in North America and other regions, including Chile and Israel. Novo’s position, by contrast, was that the treatment effect shown in Phase 2 was attributable entirely to data from the Bulgaria site, which Novo said was not properly disclosed or was otherwise misrepresented at the time of acquisition.
In early 2023, Novo became interested in acquiring Ocedurenone while Phase 3 was ongoing. Novo conducted due diligence in February 2023 and had access to a full electronic data room containing documents uploaded by KBP. The due diligence included a listing of vital signs data for every Phase 2 patient, uploaded in PDF form, and a set of documents previously submitted to the Chinese National Medical Products Administration. Following due diligence, Novo and KBP executed an asset purchase agreement on 11 October 2023, and the acquisition closed on 29 November 2023. Novo paid US$700m by wire transfer and deposited US$100m in escrow for release 18 months after closing, subject to satisfaction of unsatisfied indemnification claims asserted prior to release.
Post-closing, Novo had broad rights to control and direct KBP regarding the conduct of Phase 3, even though KBP remained sponsor. Phase 3 had a protocol providing for a formal interim analysis once all trial subjects had completed week 12, to determine whether to proceed. The results prepared by Parexel indicated that futility criteria were fulfilled, meaning the drug lacked efficacy (“Futility Determination”). Novo publicly announced in June 2024 that Phase 3 had failed and that it would take a substantial impairment loss. Novo then conducted a GCP audit of the Bulgaria site, which resulted in “major” findings concerning quality and integrity of data. Novo also presented data anomalies to KBP executives, including Dr Yang and KBP’s CEO, Dr Bing Li, including that Bulgaria was an outlier in terms of treatment effect. Further exchanges followed, including a Parexel release of topline analysis based on the locked Phase 3 database. Novo then made complaints to regulators, and KBP prepared rebuttal materials. These developments formed the factual backdrop to Novo’s fraud allegations in the arbitration and to the interim freezing relief sought in Singapore.
What Were the Key Legal Issues?
The principal issues were whether the defendants had established grounds to set aside the worldwide freezing order. In Mareva injunction applications, the court typically considers whether the claimant has a “good arguable case” on the substantive claim, whether there is a real risk that the defendant will dissipate assets to frustrate enforcement, and whether the claimant has complied with the duty of full and frank disclosure when obtaining ex parte relief.
In addition, because the freezing order was made in support of arbitration, the court had to consider the scope and requirements of its powers under s 12A of the International Arbitration Act 1994 (2020 Rev Ed). The defendants argued that the legal requirements for interim relief under s 12A were not satisfied. This required the court to assess whether the arbitral tribunal could act effectively, whether urgency justified court intervention, and whether it was appropriate for the Singapore court to make the order in the arbitration context.
How Did the Court Analyse the Issues?
On the “good arguable case” requirement, the court approached the matter as a threshold inquiry rather than a full merits determination. The judgment indicates that Novo’s fraud case was anchored in disputes about what Phase 2 data truly showed, particularly the significance of the Bulgaria site and the Interim Analysis. The court considered the defendants’ contention that Ocedurenone displayed efficacy around the world and that the Phase 2 CSR supported that view. It also considered Novo’s position that, unknown to Novo at acquisition, data from Bulgaria was responsible for showing a treatment effect in Phase 2. The court’s analysis reflects the practical reality that in complex pharmaceutical development disputes, the interpretation of trial data, the handling of interim analyses, and the disclosure of raw or underlying datasets can be central to whether there is a serious issue to be tried.
The court also examined the disclosure narrative, including whether Novo had been given sufficient information during due diligence and whether any relevant raw data was withheld or presented in a misleading way. The judgment references the disclosure of raw data during due diligence and the role of the Phase 2 Interim Analysis. It also addresses the “futility determination” in Phase 3 and how that later outcome feeds into the plausibility of Novo’s allegations about earlier representations. While the court did not decide the fraud claim finally, it treated the evidence as supporting arguable claims that could justify interim protection.
On the risk of dissipation, the court considered factual indicators that might show a likelihood of assets being moved or otherwise rendered unavailable. The judgment references the existence of external investors, the nature of KBP’s liabilities, and alleged dividends declared in 2023. It also discusses the existence of a DBS charge. These factors were relevant to whether the defendants’ financial position and corporate structure created a real risk that assets could be dissipated or otherwise made difficult to reach, thereby frustrating the arbitration’s eventual award.
Importantly, the court’s reasoning suggests that the risk assessment was not confined to a single factor. Instead, it weighed the overall picture: the defendants’ corporate and financing arrangements, their liabilities, and the practical ability of Novo to recover if it succeeded. In freezing order jurisprudence, the court does not require proof of actual dissipation; it requires a real risk. The judgment indicates that the evidence before the court met that threshold.
On full and frank disclosure, the defendants alleged breaches. The court’s analysis focused on whether any non-disclosure or misstatement was material to the ex parte decision to grant the freezing order. The judgment references “full and frank disclosure” and “facts relating to good arguable case”, including Phase 2 results, disclosure of raw data during due diligence, and the futility determination. This structure indicates that the court treated disclosure compliance as intertwined with the substantive threshold issues. The court ultimately dismissed the allegation that disclosure breaches warranted setting aside. This implies that either the alleged omissions were not material, or the claimant’s presentation of the evidence was sufficiently accurate and complete for the ex parte decision-making process.
Finally, the court addressed s 12A of the International Arbitration Act 1994. The judgment contains a dedicated analysis of “Section 12A of the IAA”, including whether the arbitral tribunal was able to act effectively, urgency, appropriateness for the Singapore court to make the order, and variation of the order. The court held that the arbitral tribunal was not positioned to provide effective interim relief in time, or that the circumstances required immediate protective measures. It also considered urgency as a key factor: freezing orders are inherently time-sensitive because the risk of dissipation can materialise quickly. The court further assessed appropriateness, which in this context involves balancing the need to protect the claimant’s position with the supervisory role of the Singapore court in arbitration-related interim relief.
The judgment also addresses variation of the order, suggesting that the defendants sought adjustments as part of their challenge. The court’s conclusion that the application should be dismissed indicates that it found no basis to vary or discharge the freezing order at that stage. The court’s approach reflects a cautious stance: where the statutory conditions are met and the threshold requirements for a Mareva injunction are satisfied, the court will generally maintain the protective order unless a clear error or material deficiency is shown.
What Was the Outcome?
The court dismissed the defendants’ application to set aside the worldwide freezing order. As a result, the freezing order remained in force, continuing to prevent KBP and Dr Huang from removing assets in Singapore up to the value of US$730m.
Practically, the decision preserves Novo’s ability to secure the effectiveness of any eventual arbitral award. It also confirms that, in Singapore, courts will uphold interim freezing relief in support of arbitration where the claimant demonstrates a good arguable case, a real risk of dissipation, and compliance with the duty of full and frank disclosure, and where s 12A’s requirements are satisfied.
Why Does This Case Matter?
This case is significant for arbitration practitioners because it illustrates how the Singapore courts apply the Mareva injunction framework when the interim relief is sought in aid of arbitration. The decision reinforces that s 12A of the International Arbitration Act 1994 is not merely procedural; it is a substantive gateway that requires the court to consider tribunal effectiveness, urgency, and appropriateness. At the same time, the court’s willingness to dismiss a set-aside application underscores that once the threshold requirements are met, the bar for discharge is not low.
For claimants, the decision highlights the importance of presenting a coherent evidential narrative at the ex parte stage. The court’s analysis of good arguable case and disclosure suggests that even in complex scientific and regulatory disputes, the court will focus on whether the claimant has raised serious issues supported by evidence, including how trial data was handled and what was disclosed during due diligence. For respondents, the decision demonstrates that allegations of non-disclosure and lack of dissipation risk must be supported by materiality and substance; bare assertions are unlikely to succeed.
For law students and researchers, the judgment is also useful as a structured example of how courts integrate (i) Mareva principles, (ii) the duty of full and frank disclosure, and (iii) the arbitration-specific statutory considerations under s 12A. The case therefore serves as a reference point for future applications involving worldwide freezing orders in support of international arbitration.
Legislation Referenced
- International Arbitration Act 1994 (2020 Rev Ed), s 12A
Cases Cited
- (Not provided in the supplied extract.)
Source Documents
This article analyses [2025] SGHCI 22 for legal research and educational purposes. It does not constitute legal advice. Readers should consult the full judgment for the Court's complete reasoning.